Sotrastaurin single-dose pharmacokinetics in de novo liver transplant recipients
- 7 December 2010
- journal article
- clinical trial
- Published by Frontiers Media SA in Transplant International
- Vol. 24 (3) , 276-283
Abstract
P>Sotrastaurin is a protein kinase C inhibitor in development for prevention of rejection after liver transplantation. In a pharmacokinetic study, 13 de novo liver transplant recipients received 100 mg sotrastaurin once between days 1-3 and once between days 5-8 post-transplant. Sotrastaurin absorption based on the area under the concentration-time curve (AUC) of total drug in blood (3544 +/- 1434 ng center dot h/ml) was similar to that of healthy subjects in a previous study (4531 +/- 1650 ng center dot h/ml). However, the sotrastaurin binding protein, alpha 1-acid glycoprotein, was nominally higher in patients (1.07 +/- 0.28 vs. 0.87 +/- 0.16 g/l, P = 0.13) yielding a 60% lower AUC based on free drug versus that in healthy subjects (27 +/- 13 vs. 62 +/- 15 ng center dot h/ml, P < 0.0001). There was minor excretion of sotrastaurin in drained bile (1% of dose) consistent with the fact that sotrastaurin is extensively metabolized leaving little unchanged drug to excrete. In the first week after liver transplantation, sotrastaurin is bioavailable after oral administration. However, patients with elevated alpha 1-acid glycoprotein levels may have lower free drug concentrations. Whether a higher dose of sotrastaurin is needed to compensate for this in the short-term after surgery will be addressed in future clinical trialsKeywords
This publication has 12 references indexed in Scilit:
- Sotrastaurin and Tacrolimus Coadministration: Effects on Pharmacokinetics and Biomarker ResponsesThe Journal of Clinical Pharmacology, 2010
- Sotrastaurin, a Novel Small Molecule Inhibiting Protein Kinase C: First Clinical Results in Renal‐Transplant RecipientsAmerican Journal of Transplantation, 2010
- Effects of the novel protein kinase C inhibitor AEB071 (Sotrastaurin) on rat cardiac allograft survival using single agent treatment or combination therapy with cyclosporine, everolimus or FTY720Transplant International, 2009
- The PKC inhibitor AEB071 may be a therapeutic option for psoriasisJournal of Clinical Investigation, 2008
- Conversion of Stable Liver Transplant Recipients From a Twice-Daily Prograf-Based Regimen to a Once-Daily Modified Release Tacrolimus-Based RegimenTransplantation Proceedings, 2005
- Changes in Tacrolimus Distribution in Blood and Plasma Protein Binding Following Liver TransplantationTherapeutic Drug Monitoring, 2004
- The Hummel–Dreyer method: impact in pharmacologyBiomedical Chromatography, 2003
- Development and validation of a 96-well equilibrium dialysis apparatus for measuring plasma protein bindingJournal of Pharmaceutical Sciences, 2003
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- BILE-INDEPENDENT ABSORPTION OF CYCLOSPORINE FROM A MICROEMULSION FORMULATION IN LIVER TRANSPLANT PATIENTSTransplantation, 1995